Clindamycin

C difficile risk
High
Oral Bioavailability
Excellent
Cost
PO ~$1/day IV ~ $14-17/day

Dosing

Usual indications 600 mg IV q8h

Necrotizing SSTI or toxic shock syndrome 900mg IV q8h

Oral Dosing 300 mg PO q6h

IVPO40 mg/kg/day divided q6-8h30-40 mg/kg/day divided q6-8h

General Information

In addition to other agents for necrotizing fascitis or toxic shock syndrome.

  • Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

  • For decreasing toxin production in toxic shock syndrome.

  • Anaerobic infections above the diaphragm, especially dental infection.

  • Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta-lactam for reducing toxin production.

  • Skin & soft tissue infections involving susceptible MRSA.

Monitor for diarrhea.

  • Muscle relaxants, e.g., Atracurium, Baclofen, Diazepam.

  • St. Johns Wort

Not a great empiric drug for coverage of MRSA based on local susceptibility profiles.

High risk for C. difficile infection.

Antimicrobial class: Lincosamide

Pregnancy category: B

Average serum half life: 2.4 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor

No renal adjustment required

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.